978 related articles for article (PubMed ID: 19007201)
1. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
2. Pyrazole NNRTIs 1: design and initial optimisation of a novel template.
Mowbray CE; Burt C; Corbau R; Perros M; Tran I; Stupple PA; Webster R; Wood A
Bioorg Med Chem Lett; 2009 Oct; 19(19):5599-602. PubMed ID: 19709880
[TBL] [Abstract][Full Text] [Related]
3. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
[TBL] [Abstract][Full Text] [Related]
5. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
[TBL] [Abstract][Full Text] [Related]
8. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
9. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
[TBL] [Abstract][Full Text] [Related]
10. Arylthiopyrrole (AThP) derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis, structure-activity relationships, and docking studies (part 2).
Lavecchia A; Costi R; Artico M; Miele G; Novellino E; Bergamini A; Crespan E; Maga G; Di Santo R
ChemMedChem; 2006 Dec; 1(12):1379-90. PubMed ID: 17089434
[TBL] [Abstract][Full Text] [Related]
11. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
12. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
[TBL] [Abstract][Full Text] [Related]
13. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
14. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C
J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
Rawal RK; Tripathi R; Katti SB; Pannecouque C; De Clercq E
Eur J Med Chem; 2008 Dec; 43(12):2800-6. PubMed ID: 18242784
[TBL] [Abstract][Full Text] [Related]
16. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mitchell ML; Son JC; Lee IY; Lee CK; Kim HS; Guo H; Wang J; Hayes J; Wang M; Paul A; Lansdon EB; Chen JM; Eisenberg G; Geleziunas R; Xu L; Kim CU
Bioorg Med Chem Lett; 2010 Mar; 20(5):1585-8. PubMed ID: 20137928
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
[TBL] [Abstract][Full Text] [Related]
18. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
Monforte AM; Logoteta P; Ferro S; De Luca L; Iraci N; Maga G; Clercq ED; Pannecouque C; Chimirri A
Bioorg Med Chem; 2009 Aug; 17(16):5962-7. PubMed ID: 19616956
[TBL] [Abstract][Full Text] [Related]
20. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
